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Abstract
Background: Dipeptidyl peptidase IV (DPPIV) also known as the T cell activation marker CD26 is a multifunctional
protein which is involved in various biological processes. The association of human-DPPIV with components of the
human immunodeficiency virus type-1 (HIV1) is well documented and raised some discussions. Several reports
implicated the interaction of human-DPPIV with the HIV1 transcription transactivator protein (HIV1-Tat) and the
inhibition of the dipeptidyl peptidase activity of DPPIV by the HIV1-Tat protein. Furthermore, enzyme kinetic data
implied another binding site for the HIV1-Tat other than the active centre of DPPIV. However, the biological
significance of this interaction of the HIV1-Tat protein and human-DPPIV has not been studied, yet. Therefore, we
focused on the interaction of HIV1-Tat protein with DPPIV and investigated the subsequent biological
consequences of this interaction in Spodoptera frugiperda cells, using the BAC-TO-BAC baculovirus system.
Results: The HIV1-Tat protein (Tat-BRU) co-localized and co-immunoprecipitated with human-DPPIV protein,
following co-expression in the baculovirus-driven Sf9 cell expression system. Furthermore, tyrosine phosphorylation
of DPPIV protein was up-regulated in Tat/DPPIV-co-expressing cells after 72 h culturing and also in DPPIV-
expressing Sf9 cells after application of purified recombinant Tat protein. As opposed to the expression of Tat
alone, serine phosphorylation of the Tat protein was decreased when co-expressed with human-DPPIV protein.
Conclusions: We show for the first time that human-DPPIV and HIV1-Tat co-immunoprecipitate. Furthermore, our
findings indicate that the interaction of HIV1-Tat and human-DPPIV may be involved in signalling platforms that
regulate the biological function of both human-DPPIV and HIV1-Tat.
Background
Dipeptidyl peptidase IV (DPPIV, CD26, EC: 3.4.14.5) is a
type II transmembrane sialoglycoprotein which belongs
to the prolyl oligopeptidase family of serine proteases
[1,2]. DPPIV cleaves dipeptides from the N-terminus of
oligopeptides with proline or alanine in their penulti-
mate position [3,4]. Physiological substrates of DPPIV
include chemokines, peptide hormones and neuropep-
tides. However, additional roles have been assigned to
DPPIV that are independent of its proteolytic activity.
These include cell-adhesion by binding to collagen and
fibronectin [5,6] as well as regulation of immune
response by interacting with adenosine deaminase
(ADA) and CD45 [7-9]. Thus, DPPIV serves as a recep-
tor for the enzyme ADA, which in turn converts adeno-
sine irreversibly to inosine, thereby preventing
suppression of lymphocyte proliferation by adenosine.
There is evidence for the involvement of DPPIV in
HIV-infection and the progression of AIDS-associated
immune suppression, although DPPIV does not serve
directly as a co-receptor of HIV infection [10] as was
earlier postulated [11]. DPPIV is known to cleave many
chemokines such as stromal cell derived factor 1 (SDF-
1a/b), macrophage-derived chemokine (MDC) [12,13]
and regulated on activation normal T cell expressed and
secreted (RANTES) and regulate their biological func-
tions. Intriguingly, cleavage of RANTES and SDF-1a,
results in opposing effects regarding their anti-HIV
activities. While truncation of RANTES by DPPIV
increases its chemotactic activity via the C-C chemokine
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[14,15], cleavage of SDF-1a by DPPIV leads to reduced
chemotactic activity and consequently promotes HIV
infection via the C-X-C chemokine receptor 4 (CXCR4)
[16]. The association of CXCR4 with DPPIV further
supports the involvement of DPPIV in HIV infection
[17]. Furthermore, it has been established that the HIV1
transactivator of transcription (HIV1-Tat) associates
with and inhibits the enzymatic activity of DPPIV and
thereby suppresses the co-stimulatory signalling of
DPPIV [18-20]. The immunosuppressive effects of the
HIV1-Tat protein seem to involve the interplay between
HIV1-Tat protein, CXCR4 and DPPIV [21], since the
HIV1-Tat protein is a known antagonist of CXCR4 [22].
The HIV1-Tat protein is a small 10-12 kDa protein
that contains five distinct functional domains [23]. Its
primary role is the transactivation of transcription of
HIV proviral-DNA by binding to the transacting
response element (TAR) on the proviral long terminal
repeat (LTR) [24-26]. In the absence of Tat protein, the
transcription of viral transcripts is low and results to
production of shorter transcripts.
The HIV-Tat protein is secreted from HIV infected
cells by a poorly studied mechanism and is suggested to
have paracrine effects on uninfected cells of HIV
infected patients [27]. Extracellular Tat protein re-enters
cells via lipid rafts and caveolar up-take [28] by interact-
ing with cell surface receptors such as heparan sulphate
proteoglycans [29], the integrin receptors a5b1a n d
avb3 and the extracellular matrix proteins fibronectin
and vitronectin [30,31]. The subsequent outcome of
such re-entry of Tat into cells is diverse and poorly stu-
died. Studies with recombinant Tat protein reveal that
extracellular Tat taken-up by cells, translocates to the
nucleus where it modulates amongst others, the expres-
s i o no faw i d er a n g eo fg e n e ss u c ha sc y t o k i n e s[ 3 2 , 3 3 ] ,
chemokine receptors [34] and major histocompatibility
complex (MHC) [35,36]. Post-translational modifications
of the Tat protein are well documented [37-39], which
offer the protein a wide range of functions that are still
poorly understood.
The association of extracellular HIV1-Tat protein to
DPPIV on the cell membrane and its internalization due
to this association is unresolved [18,40]. These discre-
pancies may lie in the methods used and also the obser-
vation that extracellular HIV1-Tat protein is an
opportunist that uses different cell surface proteins to
attach to the surfaces of different cell types prior to its
internalization. Thus, purified HIV1-Tat protein can be
internalized by different cell types irrespective of the
expression of DPPIV or some of the already charac-
terised cell surface proteins it uses for internalization
[28-30]. Presently, it is known that Tat protein plays a
vital role in the pathogenesis of AIDS. However, the
multifaceted nature of Tat protein indicates that many
of its characteristic roles in HIV-infection and the pro-
gression of AIDS are still unknown. Inhibition of DPPIV
enzyme activity and suppression of DPPIV-dependent
T-cell growth [41], are known characteristics of the Tat
protein as well as its interaction with DPPIV. However,
the mechanism behind the Tat protein-mediated sup-
pression of DPPIV-dependent T-cell growth has not
been elucidated yet. Whether the inhibition of the enzy-
matic activity of DPPIV by HIV1-Tat protein is the sole
mediator of this effect is also not known.
Therefore, we developed a simple strategy to study the
effects of HIV1-Tat protein on human-DPPIV and vice
versa in Sf9 cells using the BAC-TO-BAC baculovirus
expression system. Co-expression of HIV1-Tat and
human-DPPIV in Sf9 cells offered relatively high yields
of the proteins within a very short time. We show that
HIV1-Tat protein co-associates with human-DPPIV in
Sf9 cells. Furthermore, we demonstrate that tyrosine
phosphorylation of DPPIV is induced by purified recom-
binant Tat protein, whereas serine-phosphorylation of
HIV1-Tat is reduced due to its co-expression with
human-DPPIV.
Results and Discussion
Human-DPPIV and HIV1-Tat co-associate in co-infected
Sf9 cells
To verify whether HIV1-Tat associates with human-
DPPIV, Sf9 cells co-infected with Tat and DPPIV
recombinant baculoviruses were harvested 48 h and 72 h
post infection and stained with antibodies as described
under methods. Images of the stained cells were made at
a 100-fold magnification by confocal microscopy.
Confocal microscopy detected the Tat protein predomi-
nantly in the nucleus and cytosol and to a lesser extent on
the cell membrane (Figure 1). As expected, the DPPIV
protein is predominantly located on the cell membrane.
Staining the nuclei of cells with DAPI made it easy to dis-
tinguish the nuclei from other compartments. HIV1-Tat
and human-DPPIV co-localize at the cell membrane of Sf9
cells as indicated with arrows on merged images (Figure 1,
white arrows). Controls conducted with single and co-
infected Sf9 cells completely ruled-out non-specific bind-
ing of the antibodies used (see Additional File 1: Negative
controls for confocal microscopy). We further confirmed
the association of HIV1-Tat with human-DPPIV using co-
immunoprecipitation tests. Implementing antibodies
against Tat or DPPIV, both DPPIV and Tat protein could
be co-immunoprecipitated from Sf9 cells after 72 h co-
expression (Figure 2A and 2B). In control samples of sin-
gle expressions, neither unspecific precipitation of Tat by
the anti-DPPIV pAb (Figure 2A, lane 1) nor of DPPIV by
the anti-Tat mAb was seen (Figure 2B, lane 1). Further-
more, unspecific binding of the proteins to the protein-
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Page 2 of 12Figure 1 Co-localization of human-DPPIV and HIV1-Tat in Sf9 cells. Sf9 cells co-infected with Tat and DPPIV recombinant baculoviruses were
harvested at the indicated time then fixed on culture slides and double-stained with the antibody combination: anti-Tat mAb/anti-mouse-Cy3
(red) and anti-DPPIV pAb/anti-rabbit-FITC (green). Nuclei were stained with DAPI (blue) and images were made at 100-fold magnification by
confocal laser scanning microscopy. Co-localization of HIV1-Tat and human-DPPIV protein takes place at the cell membrane of merged images
(white arrows).
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and DPPIV undergo binding which initiates their co-
immunoprecipitation from co-infected cells. Immuno-
precipitation of Tat with anti-Tat mAb always yielded
a double band at 10 kDa and 13 kDa. We noticed that
the 13 kDa band had a higher intensity than the
10 kDa protein band when Tat was expressed alone
(Figure 2A, lane 2). Interestingly, when Tat was co-
expressed with DPPIV, immunoprecipitation with Tat
or DPPIV specific antibodies yielded predominantly
the 10 kDa band (Figure 2A, lanes 5 and 7). Co-
expressing Tat and a control recombinant baculovirus
prepared by transfecting the pFASTBAC1 cloning vec-
tor bacmid in Sf9 cells did not lead to a difference in
the intensities of the 10 kDa and 13 kDa protein bands
(Figure 2A, lane 4). This suggests that the HIV1-Tat
protein due to co-expression with human-DPPIV, but
not the high virus titre used is predominantly in the
10 kDa form. Interestingly, co-immunoprecipitation of
Tat and DPPIV was only possible when whole-cell
lysates were used. Using crude membrane extracts or
mixed cell lysates of independently expressed human-
DPPIV and HIV1-Tat protein yielded no binding of
the proteins in immunoprecipitation tests. Further-
more, solubilisation of Tat/DPPIV co-expressing Sf9
cells with Triton X100 which destroys protein-protein
contacts completely abolished their co-immunoprecipi-
tation. Taken together, it is likely that binding of Tat
and DPPIV requires some modifications or factors
which are only disposed when both proteins are co-
expressed.
Serine-phosphorylation of HIV1-Tat protein is reduced
due to human-DPPIV
To confirm whether the double Tat protein bands
resulted from posttranslational modifications, we veri-
fied if Tat expressed in the Sf9 cell system was phos-
phorylated. Precipitation of Tat protein from Tat- and
Tat/DPPIV-expressing Sf9 cells with anti-phospho-ser-
ine mAb was achieved (Figure 3A, upper panel). Only
the 13 kDa band, but not the 10 kDa band was precipi-
tated by the anti-phospho-serine mAb, opposed to both
10 kDa and 13 kDa bands precipitated by the anti-Tat
mAb from the same lysates (Figure 3A, lower panel).
Furthermore, only a faint 13 kDa band was precipitated
from Tat/DPPIV-expressing Sf9 cells, suggesting that
phosphorylation of HIV1-Tat protein was reduced due
to its co-expression with DPPIV. Assuming that the
level of phosphorylation of Tat protein being expressed
alone for 72 h is 100%, the phosphorylation level after
48 h was 59% (Figure 3B). Only 22% of phospho-Tat
protein was realized after 72 h co-expression with
DPPIV. Co-infecting Sf9 cells with HIV1-Tat- and the
control vector-virus did not influence the level of ser-
ine-phosphorylation of Tat, suggesting that the decrease
in the pool of phospho-Tat in Tat/DPPIV samples was
not due to the high titre of virus used in co-infection,
but rather due to DPPIV.
To further confirm whether the 13 kDa band was pre-
cipitated due to phosphorylation and not unspecific
binding to the antibody, lysates of HIV1-Tat being
expressed alone or together with human-DPPIV for 72 h
were either treated with alkaline phosphatase or left
untreated, then subsequently immunoprecipitated with
the anti-phospho-serine mAb or anti-Tat mAb. The
treatment of lysates with increasing concentrations of
alkaline phosphatase led to a decrease in the immunopre-
cipitation of phospho-Tat protein with anti-phospho-ser-
i n em A b( F i g u r e3 C ,l a n e s2 - 4 ,u p p e rp a n e l ) ,s ot h a t
treatment with 1 U alkaline phosphatase/100 μg proteins
removed almost all the phosphates and almost completely
abolished precipitation of Tat by the anti-phospho-serine
m A b( F i g u r e3 C ,l a n e4 ,u p p e rp a n e l ) .O p p o s e dt ot h i s ,
immunoprecipitation with anti-Tat mAb yielded relatively
uniform intensities of the Tat protein, irrespective of the
concentration of the alkaline phosphatase used (Figure 3C,
lanes 2-4, lower panel). The HIV1-Tat protein (Tat-BRU)
expressed in this study has only one tyrosine residue
(Y-47). Precipitation of Tat protein with anti-phospho-
tyrosine mAb was not detected.
It has been established earlier, that phosphorylation of
Tat protein takes place on serine-16 and serine-46 and
is important in regulating the level of transcription of
Lysate: Tat Tat/DPPIV A
B Lysate: DPPIV Tat/DPPIV 
75 kDa
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13 kDa
10 kDa
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Figure 2 Co-immunoprecipitation of human-DPPIV and HIV1-
Tat protein from Sf9 cells. Single expression or co-expression of
Tat with DPPIV was performed for 72 hours, afterwards the cells
were solubilised and lysates subjected to immunoprecipitation, (IP).
(A) IP was conducted with anti-Tat mAb (lanes 2, 4 and 5) or with
anti-DPPIV pAb (lanes 1, 3 and 7). Lane 6 was control conducted
with protein-A-sepharose without antibody. Tat/vector represents
control cells co-infected with Tat and a pFASTBAC1 vector virus.
Each immunoprecipitate was separated by SDS-PAGE and the gels
blotted and probed for with anti-Tat mAb. (B) IP was conducted
with anti-Tat mAb (lanes 1 and 5) or with anti-DPPIV pAb (lanes 2
and 3) or with protein-A-sepharose without antibody (lane 4). The
immunoprecipitates were subsequently blotted and probed for with
anti-DPPIV pAb. The figure represents one of three independent
experimental results.
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serine-46 to alanine resulted in a 3-fold decrease in Tat
transactivation activity [38]. Our results show that serine
phosphorylation of the HIV1-Tat protein is reduced due
to its co-expression with DPPIV, suggesting that DPPIV
plays a regulatory role in HIV transcription. Besides phos-
phorylation, other post-translational modifications of
HIV1-Tat protein such as acetylation, lysine-methylation
and ubiquitination contribute in regulating Tat’s function
as a transcription activator [37,42,43]. Although we did
not investigate the effect of DPPIV on the acetylation,
methylation or ubiquitination of Tat protein in Sf9 cells, it
seems likely that some of these modifications are altered
when HIV1-Tat is co-expressed with human-DPPIV. Tat
being expressed alone yields both a 10 kDa and a 13 kDa
modified protein, but the 10 kDa protein predominantly
when co-expressed with DPPIV. Phosphorylation alone
(on serine-16 and serine-46) cannot result to the 3 kDa
molecular mass difference observed in the Tat protein
bands. Furthermore, treatment of lysates of Tat-expressing
Sf9 cells with increasing concentrations of alkaline phos-
phatase did not result in a significant increase or decrease
in the intensity and mass of the Tat protein bands precipi-
tated with anti-Tat mAb (Figure 3C, lower panel), but sig-
nificantly reduced the precipitation of phospho-Tat by
anti-phospho-serine mAb (Figure 3C, upper panel). These
findings suggest that phosphorylation and probably other
unknown posttranslational modifications of HIV1-Tat are
altered due to its co-expression with human-DPPIV,
which are involved in regulating Tat transactivation
activity.
HIV1-Tat induces tyrosine phosphorylation of human-
DPPIV in Sf9 cells
DPPIV expressed in Sf9 cells was phosphorylated on tyr-
o s i n er e s i d u e sa n dc o u l db ei m m u n o p r e c i p i t a t e dw i t h
Figure 3 Human-DPPIV causes a decrease in phosphorylation of HIV1-Tat in Sf9 cells.( A) Lysates of Tat-expressing Sf9 cells harvested at
the indicated time were subjected to IP with anti-phospho-serine mAb (upper panel) or anti-Tat mAb (lower panel). Each immunoprecipitate
was separated by SDS-PAGE, blotted and subsequently probed for with anti-Tat mAb. The band in lane 4 (lower panel) was cut from another
position of the same blot. (B) The intensities of phospho-Tat protein bands were determined with the QuantityOne software and calibrated
against the respective intensities of the total proteins. Tat being expressed alone for 72 h was taken as standard (= 100%). Each bar represents
the relative phosphorylation level deduced from 3 independent experiments ± standard deviations as a percentage of the standard. (C) Lysates
of Tat-expressing Sf9 cells were treated with different concentrations of alkaline phosphatase for 2 h at 37°C as follows: 1 U alkaline
phosphatase/500 μg protein (lane 2), 1 U alkaline phosphatase/200 μg protein (lane 3) or 1 U alkaline phosphatase/100 μg protein (lane 4).
Control samples were left untreated (lane 1 and lane 5) then immunoprecipitated with the anti-phospho-serine mAb (upper panel) or anti-Tat
mAb (lower panel). The immunoprecipitates were blotted and subsequently probed for with anti-Tat mAb.
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lation was increased in the lysates of DPPIV-expressing
cells that were treated with 2.7 nM final concentration
of the purified recombinant Tat protein (GST-Tat-His)
for 22 h and also in Tat/DPPIV-expressing cells after 72 h
co-expression (Figure 4A, lanes 4 and 7 upper panel).
With reference to untreated DPPIV being expressed
alone for 72 h (Figure 4A, lane 3), the phosphorylation of
DPPIV after application of purified Tat protein was
increased by 9 folds and that of Tat/DPPIV sample by 8
folds (Figure 4B). Co-infecting cells with DPPIV and the
control vector virus for 72 h did not lead to the increase
in the pool of phospho-DPPIV seen in Tat/DPPIV-
expressing cells (Figure 4A, lanes 1 and 7), making it evi-
dent that HIV1-Tat and not the high titre of virus used
i nc o - e x p r e s s i o n si sr e s p o n s ible for the induction of
DPPIV tyrosine phosphorylation.
It has been established, that the N-terminal sequence
of HIV1-Tat protein is responsible for the inhibition of
the enzymatic activity of DPPIV [44]. The purified
recombinant Tat protein applied to cells in this study
carried an N-terminal Glutathione-S-Transferase (GST)
fusion-tag which eased its purification from E. coli.T h e
GST-Tat-His protein revealed a strong ability to trans-
activate the HIV1-LTR promoter in a stably transfected
HeLa cell line (see Additional File 2: Determination of
the transactivation activity of recombinant Tat protein),
but was unable to inhibit the enzymatic activity of puri-
fied human-DPPIV in vitro (see Additional File 3: Deter-
mination of the ability of recombinant Tat protein to
inhibit the enzymatic activity of DPPIV), due to the
N-terminal GST-tag. To proof that Tat itself and not
the long GST-tag on the recombinant GST-Tat-His pro-
tein induced tyrosine phosphorylation of DPPIV, Sf9
cells were infected with DPPIV recombinant baculovirus
for 68 h, then a portion of the cells subsequently treated
with the purified recombinant GST-Tat-His or GST
protein for 4 h. Reducing the induction time to 4 h still
led to a significant increase in tyrosine phosphorylation
of DPPIV in the Tat-treated samples (Figure 4C, lane 4),
opposed to the GST-treated sample (Figure 4C, lanes 1
and 2), indicating that the recombinant GST-Tat-His
protein induced tyrosine phosphorylation of human-
DPPIV in Sf9 cells due to Tat and not the GST-tag.
Furthermore, treatment of sample lysates with alkaline
phosphatase prior to immunoprecipitation with the anti-
phospho-tyrosine mAb abolished the immunoprecipita-
tion of DPPIV (Figure 4C, lane 3), indicating that the
anti-phospho-tyrosine mAb used is specific for recogni-
tion of tyrosine-phosphorylated proteins.
Co-expression of Tat and DPPIV yielded only traces of
phospho-DPPIV at expression durations 24 h and 48 h.
At 72 h co-expression, the pool of phospho-DPPIV
increased significantly (Figure 4A, lane 5-7), suggesting
that the level of the Tat protein expressed at this stage
may play a role in the induction of tyrosine phosphoryla-
tion of DPPIV. However, detectable traces of Tat protein
were secreted to the culture medium at this stage of
expression (result not shown) suggesting that the con-
centration of Tat protein in the culture medium may also
play a role in tyrosine phosphorylation of DPPIV. Selec-
tive activation of a variety of protein kinases by extracel-
lular Tat protein in other cell systems has been
documented [45-47].
Taken together, our results using the purified GST-
Tat-His protein suggest that the inhibition effect of Tat
protein on the enzyme activity of DPPIV is not a prere-
quisite for its induction of the phosphorylation of
DPPIV on tyrosine residues. Furthermore, treating
DPPIV- and Tat/DPPIV-expressing Sf9 cells previously
cultured for 48 h with the DPPIV-inhibitor Ile-Pro-Ile
for 4.5 h did not induce an increase in tyrosine phos-
phorylation of DPPIV in the cells (result not shown).
These observations suggest that N-terminal binding of
HIV1-Tat protein to the active site of human-DPPIV
may result in inhibition, whereas interaction of Tat pro-
tein to the glycan moieties may lead to phosphorylation
of DPPIV [19] and result to different signalling cascades.
Interestingly, DPPIV-inhibitor dependent induction of
tyrosine phosphorylation of several proteins in resting
T cells was reported earlier [48]. However, high expres-
sion of DPPIV is restricted to activated T cells [49]
which explains why the study did not detect phospho-
DPPIV. Furthermore, Tat-dependent induction of apop-
tosis in resting T cells was also documented which was
associated with enhanced activation of cyclin-dependent
kinases [50]. Generally, apoptotic effects of specific inhi-
bitors of DPPIV have not been reported so far, which
makes them suitable therapeutic drugs in the treatment
of diabetes mellitus type-2 [51]. Taken together, these
findings support our observation that the effect of Tat
protein on DPPIV is not only dependent on its inhibi-
tion capacity, but also dependent on the activation of
other signalling cascades involving DPPIV tyrosine
phosphorylation. Recently, insulin-dependent tyrosine
phosphorylation of DPPIV in rat liver was reported and
the DPPIV protein levels were shown to be down-regu-
lated by 40% in both plasma membrane and Golgi/ER
fractions after addition of the tyrosine phosphatase inhi-
bitor bpV (phen) [52]. This finding in rat liver revealed
that tyrosine phosphorylation of DPPIV is associated
with the stability and signalling activity of DPPIV. The
stability and level of DPPIV is important in its interac-
tion with CD45 and in the co-stimulation of T cell acti-
vation. In accordance with this, high level of DPPIV
expression is restricted to activated T cells [49].
T h es i m p l es t r a t e g yd e s i g n e di nt h eu n d e r l y i n gw o r k
using the BAC-TO-BAC baculovirus-driven Sf9
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Figure 4 HIV1-Tat induces tyrosine phosphorylation of human-DPPIV in Sf9 cells.( A) Sf9 cells were infected with the indicated
recombinant baculoviruses. After 50 h a portion of the DPPIV-expressing cells were treated with 2.7 nM final concentration of purified
recombinant Tat protein (GTH: GST-Tat-His), and cultured for further 22 h. The resulting cell lysates were subsequently subjected to IP with anti-
phospho-tyrosine mAb (upper panel) or anti-DPPIV pAb (lower panel). Each immunoprecipitate was separated by SDS-PAGE, blotted and probed
for with anti-DPPIV pAb. DPPIV/vector: cells co-infected with DPPIV- and a control pFASTBAC1-vector recombinant virus. (B) The band intensities
of phospho-DPPIV protein (in B, upper panel) were quantified with the QuantityOne software (Bio-Rad) and calibrated against the total DPPIV
protein. The value of DPPIV being expressed alone for 72 h was set as standard (= 1) and the relative phosphorylation fold deduced as quotients
of the values got for the other samples and the standard. (C) Sf9 cells were infected with DPPIV recombinant baculovirus and cultured for 68 h
then treated with GST-Tat-His or GST and cultured for further 4 h. After solubilisation, each lysate was divided into two equal portions and either
treated with alkaline phosphatase (lanes 1 and 3) or left untreated (lanes 2 and 4). The lysates were subjected to IP with anti-phospho-tyrosine
mAb (upper panel) or anti-DPPIV pAb (lower panel). Immunoprecipitates were separated by SDS-PAGE, blotted and subsequently probed for
with anti-DPPIV pAb. The figure represents one of three independent experimental results.
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both HIV1-Tat and human-DPPIV and is suitable for
the investigation of their interaction in the cells. Owing
to the high expression levels, protein-protein associa-
tions whose detection is limited in other expression sys-
tems by low expression levels was possible. Our findings
in the Sf9 insect cell system can be argued by others as
being an artefact. However, this can be ruled out, since
both HIV1-Tat and human-DPPIV proteins purified
from the same cell system retain their specific activities.
Furthermore, the crystal structure of human-DPPIV
protein expressed and purified from this cell system did
not reveal any differences to that purified from animal
tissues [53].
Shortly before this work was submitted for publica-
tion, the crystal structure of HIV1-Tat protein in com-
plex with human p-TEFb was elucidated following their
co-expression by the same strategy and in the same cell
system used in the underlying work [54]. This supports
the fact that the cell system iss u i t a b l ef o rt h ee x p r e s -
sion of the HIV1-Tat protein with binding partners of
human origin and strengthens the fact that the protein
modifications in our research is due to the binding part-
ners used and not due to the cell system.
Conclusion
This work points out the significance of the interaction
of HIV1-Tat and human-DPPIV and reveals further
insights towards understanding HIV infection and the
progression of AIDS. It demonstrates the co-localiza-
tion and binding of HIV1-Tat protein and human-
DPPIV in Sf9 cells. Furthermore, it reveals that serine-
phosphorylation of Tat is significantly reduced due to
its co-expression with human-DPPIV, whereas tyrosine
phosphorylation of DPPIV is strongly induced by the
HIV1-Tat protein. The findings further indicate that
the inhibition effect of Tat on the enzymatic activity of
human-DPPIV is not a prerequisite for its induction of
the tyrosine phosphorylation of DPPIV.
Materials and methods
Construction and expression of human-DPPIV and HIV1-
Tat in Sf9 cells
Expression and purification of enzymatically active
DPPIV from insect cells was reported earlier [55]. Full
length HIV1-Tat cDNA, pre-cloned into the mammalian
vector pC63.4.1, (NIBSC, AIDS Research and Reference
Reagent Program) was amplified by PCR and ligated in
the pCR-Blunt vector (Invitrogen). The cDNA was then
sub-cloned into the EcoR1 and Xba1 sites of pFAST-
BAC1 vector. After verification of its sequence by the
Sanger dideoxy chain termination method [56], the Tat-
pFASTBAC1 plasmid was transformed in the E. coli
DH10Bac cells (Invitrogen). Preparation of recombinant
bacmid, transfection into the baculovirus-driven Sf9 cells
and production of recombinant baculovirus was done
according to the manufacturer’s instructions. For protein
expression purposes, Sf9 cells at a density 2 × 10
6 cells/
ml serum-deficient medium were infected with the
recombinant baculovirus at the multiplicity of infection
(MOI) = 1. For co-expression of HIV1-Tat and human-
DPPIV, cells at the given density were co-infected with
both HIV1-Tat- and DPPIV-recombinant baculoviruses
at the MOI ratio 1:1.
Antibodies
T h ea n t i b o d i e su s e dw e r ea n t i - T a tm A b( N I B S C ,A I D S
Research and Reference Reagent Program), rabbit-anti-
human-DPPIV pAb (anti-DPPIV pAb, 9/9 prepared in
our laboratory), Cy3-conjugated-anti-mouse antibody
(anti-mouse-Cy3, Sigma), FITC-conjugated-anti-rabbit
antibody (anti-rabbit-FITC, Sigma), anti-phospho-serine
mAb (Sigma, P3430 clone PSR-45) and anti-phospho-
tyrosine mAb (Sigma, P3300 clone PT-66).
Immuno-staining and confocal microscopy
Sf9 cells co-infected with the Tat- and DPPIV-recom-
binant baculoviruses were harvested 48 and 72 h post
infection and assessed. The cells were washed, fixed on
culture slides and permeabilized with 0.1% Triton
X100 in PBS for 10 min then blocked with 1% BSA
and 1% non-fat milk in PBS, pH 8.0. The cells were
incubated with the anti-Tat mAb (diluted 1:200 in PBS
containing 0.5% BSA) for 6 h, then washed twice with
PBS and incubated with the anti-DPPIV pAb (diluted
1:200 in PBS containing 0.5% BSA) overnight. After
washing 3 times with PBS the secondary antibodies
anti-mouse-Cy3 (diluted 1:500 in PBS containing 0.5%
BSA) and anti-rabbit-FITC (diluted 1:200 in PBS con-
taining 0.5% BSA) were added to the cells simulta-
neously and incubated in the dark for 30 min. The
cells were washed 3 times with PBS then the nuclei
stained by incubating the cells for 10 min in 10 μg/ml
4’ 6-diamidin-2-phenylindole dihydrochloride (DAPI)
in PBS containing 3% formaldehyde. The cells were
then washed 3 times with PBS, air-dried, immersed in
mounting solution and assessed by confocal laser scan-
ning microscopy (Carl Zeiss LSM 410) and images
made at a 100-fold magnification. Control experiments
were performed as follows: (1) Sf9 cells expressing
either only Tat or DPPIV were double-stained and
assessed under the same conditions like the Tat/
DPPIV-expressing cells. (2) Tat/DPPIV-expressing Sf9
cells were stained with a combination of the antibodies
anti-Tat mAb/anti-mouse-Cy3/anti-rabbit-FITC or
with the combination anti-DPPIV pAb/anti-rabbit-
FITC/anti-mouse-Cy3. The cells were then assessed by
confocal microscopy as mentioned above.
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Page 8 of 12Cell lysis and solubilisation of protein
Infected Sf9 cells were harvested at the indicated expres-
sion duration and washed once with PBS, then resus-
pended and sonicated in solubilisation buffer (PBS
containing 2% n-dodecyl-b-D maltoside, 500 KU Trasy-
lol and 0.5 mM DTT). Solubilisation was performed by
4 h incubation at 4°C with head over tail rotation. Solu-
b l ep r o t e i n sw e r ef r a c t i o n a t e db yc e n t r i f u g a t i o na t
18,000 rpm (29,703 × g) for 30 min.
Determination of protein concentration
Protein concentrations were determined using the BCA
Protein Assay Reagent Kit (Pierce).
Dephosphorylation of proteins in lysates
In order to remove phosphate groups from the residues
of proteins in lysates, 500 μl samples (800 μg total pro-
tein) were diluted with 400 μl distilled water and 100 μl
10 × dephosphorylation buffer (Fermentas). A mixture
of shrimp- and calf alkaline phosphatase were added to
the final concentrations 1 U/100 μg protein, 1 U/200 μg
and 1 U/500 μg protein. The reaction mixtures were
subsequently incubated for 2 h at 37°C.
Immunoprecipitation
The following antibodies were used: anti-Tat mAb, anti-
DPPIV pAb, anti-phospho-serine mAb and anti-phos-
pho-tyrosine mAb. For each immunoprecipitation test, 2
μg of the respective antibodies were diluted with 1 ml
PBS, pH 8.0 and immobilized on 10 mg protein-A/G-
Sepharose (Pierce) by rocking overnight at 4°C. Unbound
antibody was removed by washing twice with 1 ml PBS.
Unless otherwise indicated, 250 μg sample lysates were
added and incubated for either 4 h (Tat and DPPIV co-
immunoprecipitation) or overnight (all other tests) at 4°
C. Unbound proteins were removed and samples washed
several times with washing buffer (PBS, pH 8.0 contain-
ing 0.5% n-octyl-b-D-glucopyranoside, 500 KU Trasylol
and 0.5 mM DTT). The pellets containing the precipi-
tates were subjected to western blot analyses.
Western blot analysis
Immunoprecipitates were analyzed by SDS-PAGE under
reducing and denaturing conditions. The samples were
boiled for 5 min at 98°C in reducing sample buffer (250
mM Tris-HCl pH 6.8, 20% (v/v) glycerol, 0.01% bromo-
phenol blue, 10% b-mercaptoethanol and 4% SDS) and
separated by electrophoresis. Afterwards, the gels were
blotted on nitrocellulose membrane at 250 mA for 1 h.
The membranes were blocked with 5% non-fat milk in
PBS, pH 8.0 containing 0.1% Tween 20 (Bio-Rad). Block-
ing for detection with anti-phospho-tyrosine mAb was
performed with 3% BSA in TBS, pH 7.4. Probing for
DPPIV and Tat protein was performed with anti-DPPIV
pAb and anti-Tat mAb, respectively, with each antibody
being diluted to 1: 1000 in PBS, pH 8.0 containing 0.1%
Tween 20. Secondary antibodies were Dako-Envision
horse-radish-peroxidase coupled anti-mouse/anti-rabbit
IgG (Dako-North America Inc.) for mAb and pAb,
respectively. To detect protein phosphorylated on serine-
or tyrosine residues, anti-phospho-serine mAb (diluted
to 1:1000 in PBS, pH 8.0 containing 0.1% Tween-20) and
anti-phospho-tyrosine mAb (diluted to 1:5000 in TBS,
pH 7.4 containing 1.5% BSA and 0.5% Tween 20) were
used, respectively in combination with the Dako-Envision
HRP-anti-mouse IgG.
Quantification of protein band intensities and
determination of relative phosphorylation levels
After western blotting, the intensities of phospho-Tat
or phospho-DPPIV protein bands resulting from
immunoprecipitation with either anti-phospho-serine
mAb or anti-phospho-tyrosine mAb respectively, were
quantified with the volume contour tool of the Quanti-
tyOne software (Bio-Rad) and calibrated against the
protein band intensities of respective samples precipi-
tated with anti-Tat mAb or anti-DPPIV pAb respec-
tively. To deduce the relative phosphorylation fold of
phospho-DPPIV, DPPIV expressed alone for 72 h with-
out induction with purified Tat protein was set as
standard (= 1). The quotients of the resulting values of
respective phospho-DPPIV samples after calibration
and that of the standard were then deduced as phos-
phorylation fold. The relative phosphorylation level of
Tat protein was derived as follows: after calibration
with total Tat protein, the level of phospho-Tat protein
expressed alone for 72 h was considered as standard
and taken as 100%. The levels of phospho-Tat protein
in all the other test samples were then calculated as a
percentage of this standard.
Additional material
Additional file 1: Negative controls for confocal microscopy. Sf9 cells
either infected with the Tat- or DPPIV-recombinant baculovirus were
harvested after 72 h then fixed on culture slides and double-stained with
the antibody combination: anti-Tat mAb/anti-mouse-Cy3 and anti-DPPIV
pAb/anti-rabbit-FITC. Nuclei were stained with DAPI and images made at
a 100-fold magnification by confocal laser scanning microscopy.
Unspecific binding of the anti-Tat mAb to host proteins of DPPIV
expressing cells (A) or the anti-DPPIV pAb to host proteins of Tat-
expressing cells (B) did not take place. Furthermore, Sf9 cells co-infected
with Tat and DPPIV recombinant baculoviruses were harvested after 72 h
then fixed on culture slides and double-stained with the antibody
combination: anti-Tat mAb/anti-mouse-Cy3/anti-rabbit-FITC (C), or with
anti-DPPIV pAb/anti-rabbit-FITC/anti-mouse-Cy3 (D). Nuclei were stained
with DAPI and images were made at a 100-fold magnification by
confocal laser scanning microscopy under the same conditions like the
test cells stained with both anti-Tat mAb and anti-DPPIV pAb.
Additional file 2: Determination of the transactivation activity of
recombinant Tat protein. The HIV-Tat protein binds to an RNA structure
which leads to the activation of transcriptional initiation and elongation
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for AIDS Reagents), stably transfected with the chloramphenicol acetyl
transferase (CAT) reporter gene linked to the 5’-LTR of HIV1 was cultured
on 6 well plates and grown for 24 h to achieve 60-80% confluency. Prior
to treatment with the purified Tat protein the medium was aspirated
and the cells washed once with 2 ml PBS, pH 7.2. The protein samples
(controlled for endotoxin content) were diluted with PBS to a final
concentration 0.1 μg/μl. Aliquots were mixed with culture medium to a
final concentration 125 ng/ml then added to the cells. After culturing for
24 h the medium was changed against fresh culture medium and the
cells subjected to a further incubation for 24 h. Purified non-tagged
recombinant Tat protein (Immuno-Diagnostics, USA) was used as positive
control. Tat storage buffer (50 mM Tris pH 8.0, 200 mM KCl, 5 mM DTT),
the Tat translocation peptide Tat47-57 (Genscript Corp) and purified GST
protein were used as negative controls. The cells were harvested and
evaluated for the expression of CAT protein by use of the commercially
available CAT-ELISA kit (Pierce, Rockford, USA). Briefly, cells were lysed
and fractionated by centrifugation. The total protein concentration of
each sample was determined by the BCA method and equivalent
protein concentrations per sample were used for CAT assay according to
manufacturer’s instructions. The amount of CAT expressed/ml/μg Tat
protein used was determined and the results of 3 independent
experiments ± standard deviation presented in a bar diagram. The
purified GST-Tat-His protein revealed the highest transactivation capacity.
The Tat protein from Immuno-Diagnostics (Tat +ve) which served as a
positive control also revealed high transactivation ability. Compared to
this, the commercial Tat47-57 peptide was unable to activate the HIV-
LTR, which is in accordance with the fact that recognition and binding
of the HIV transacting response element on the LTR and activation
requires other domains of the HIV-Tat protein.
Additional file 3: Determination of the ability of purified
recombinant Tat protein to inhibit the cleavage of Glucagon-Like-
Peptide-1 by purified human-DPPIV protein. DPPIV cleavage of
Glucagon-like-peptide 1 (GLP1, Genscript Corp) was evaluated by
measuring the mass spectra of cleaved substrate at different time points
by MALDI-TOF mass spectrometry. To proof the inhibitory effect of the
HIV1-Tat protein on the enzymatic activity of DPPIV, E. coli expressed, full
length Tat-1-86 protein (Immuno-Diagnostics, USA) and the GST-Tat-His
protein bearing an N-terminal GST-fusion tag were used. The human-
DPPIV protein used was expressed in Sf9 cells and purified in two-steps
by immuno-affinity chromatography and size-exclusion chromatography.
A 100 μl assay sample composed of (final concentrat ions) 17 mM Tris
pH 8.0, 20 mM KCl, 15 mM NaCl, 0.5 mM DTT, 16 nM DPPIV, 31.25 μM
GLP1 and either 1 μM Tat-1-86 or 1 μM GST-Tat-His. The substrate was
added last in each test. For assays without Tat, equivalent volume of Tat
storage buffer (50 mM Tris pH 8.0, 200 mM KCl, 5 mM DTT) was added
to the mixture. After pippetting all assay components, 5 μl was qui ckly
removed and added to 0.5 μl of a 1% tri-fluoro acetic acid (TFA) solution
to stop the reaction. This sample was at time, t = 0. The assay mixture
was incubated at 37°C and aliquots of 5 μl removed at 5 min intervals
(for 15 min) and stopped with TFA. 1 μl of the re action mixtures at
time-points t = 0, 5, 10 and 15 min were spotted on a MALDI target and
the masses of proteolytically derived GLP1 were measured on a Bruker
Ultra Flex-III MALDI-TOF mass spectrometer (Bruker, Bremen, Germany)
with a-cyano-4-hydroxycinnamic acid (ACCA, 10 mg/ml in 70%
acetonitrile and 0.1% TFA) as matrix. The mass spectra of GLP1 were
monitored during cleavage by DPPIV in the absence of Tat protein (A) or
in the presence of 1 μM Tat (B) or 1 μM GST-Tat-His (C) respectively.
Uncleaved GLP1(7-36) has a mass of 3296 Da, whereas GLP1(9-36) results
from proteolytic cleavage by DPPIV and has a mass of about 3088 Da. In
the absence of Tat protein and in the presence of the GST-Tat-His
protein, 16 nM DPPIV cleaved up 31.25 μM GLP1 within 5 min, indicating
that the GST-Tat-His has no inhibitory effect on DPPIV. In the presence of
1 μM of the Tat-1-86 only about 40% of the GLP1 was cleaved after 5
min, indicating that Tat protein with the free N-terminus has inhibitory
effect on the enzymatic activity of DPPIV.
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